Zydus Lifesciences is currently trading at RS 893.25, up by 4.25 points or 0.48% from its previous closing of RS 889.00 on the BSE.

The stock opened at RS 893.30 and recorded a high of RS 897.20 and a low of RS 885.60. A total of 3,143 shares have been traded so far.

The BSE Group 'A' stock, with a face value of RS 1, hit a 52-week high of RS 1323.90 on August 9, 2024, and a 52-week low of RS 859.15 on March 4, 2025. Over the past week, the stock's high and low were RS 917.25 and RS 872.30, respectively. The company’s current market capitalization stands at RS 89,514.58 crore.

Promoters hold a 74.98% stake in the company, while institutional and non-institutional investors hold 18.18% and 6.84%, respectively.

In a strategic move, Zynext Ventures USA LLC, the venture capital arm of Zydus Lifesciences, has invested in Illexcor Therapeutics. Illexcor is a biopharmaceutical company developing next-generation oral therapies for sickle cell disease (SCD). This investment aligns with Zynext Ventures' goal of supporting breakthrough healthcare innovations addressing critical medical needs.

Illexcor's lead asset, currently in preclinical development, is designed to bind to Hemoglobin S, preventing polymerization and sickling of red blood cells, potentially offering a disease-modifying treatment for SCD.

Zydus Lifesciences, formerly Cadila Healthcare, is an integrated pharmaceutical company engaged in research, development, production, marketing, and distribution of pharmaceutical products.